BioCentury
ARTICLE | Clinical News

subcutaneous Binocrit epoetin alfa regulatory update

April 25, 2016 7:00 AM UTC

The European Commission approved subcutaneous Binocrit epoetin alfa from Novartis’ Sandoz division to treat anemia in patients with chronic renal failure (CRF). Sandoz already markets an IV formulatio...